Our results indicate that pre-treatment sPD-1 and AFP are predictive of HCC development during NA treatment, and the predictive accuracy is increased using a combination of serum pre-treatment sPD-1 and AFP levels (Fig. 2). Here, HOXD13 is linked to hepatocellular carcinoma.